Treatment of Staphylococcus aureus infections: new issues, emerging therapies and future directions (Q36758570)

16 August 2017

1 reference

title

Treatment of Staphylococcus aureus infections: new issues, emerging therapies and future directions (English)

1 reference

16 August 2017

Staphylococcus aureus

1 reference

Benjamin P Howden

2

0 references

author name string

Emma J Bishop

series ordinal

1

1 reference

PubMed ID

17355211

16 August 2017

language of work or name

English

0 references

publication date

1 March 2007

1 reference

Expert Opinion on Emerging Drugs

16 August 2017

1 reference

16 August 2017

12

1 reference

16 August 2017

1

1 reference

16 August 2017

1-22

1 reference

Staphylococcus aureus infections

16 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Therapeutic options for Gram-positive infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Epidemiology, clinical features and management of infections due to community methicillin-resistant Staphylococcus aureus (cMRSA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

The changing epidemiology of Staphylococcus aureus?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Prevalence of Staphylococcus aureus nasal colonization in the United States, 2001-2002.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Staphylococcus aureus bacteremia, Australia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Nasal carriage as a source of Staphylococcus aureus bacteremia. Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

“Celbenin” - resistant Staphylococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Molecular cloning of the gene of a penicillin-binding protein supposed to cause high resistance to beta-lactam antibiotics in Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Methicillin-resistant Staphylococcus aureus: an evolutionary, epidemiologic, and therapeutic odyssey

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2003, issued August 2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Epidemiology and susceptibility of 3,051 Staphylococcus aureus isolates from 25 university hospitals participating in the European SENTRY study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

The economic impact of Staphylococcus aureus infection in New York City hospitals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Epidemiology of methicillin-resistant Staphylococcus aureus (MRSA) in Sweden 2000-2003, increasing incidence and regional differences

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

The burden of Staphylococcus aureus infections on hospitals in the United States: an analysis of the 2000 and 2001 Nationwide Inpatient Sample Database

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Costs of hospital-acquired methicillin-resistant Staphylococcus aureus (MRSA) and its control

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Clinical and economic impact of methicillin resistance in patients with Staphylococcus aureus bacteremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Emergence of community-acquired methicillin-resistant Staphylococcus aureus USA 300 clone as the predominant cause of skin and soft-tissue infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

A high-morbidity outbreak of methicillin-resistant Staphylococcus aureus among players on a college football team, facilitated by cosmetic body shaving and turf burns

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Community-acquired methicillin-resistant Staphylococcus aureus among military recruits

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Community-acquired methicillin-resistant Staphylococcus aureus in a rural American Indian community.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Methicillin-resistant Staphylococcus aureus. Epidemiologic observations during a community-acquired outbreak

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Association between Staphylococcus aureus strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Is Panton-Valentine leukocidin the major virulence determinant in community-associated methicillin-resistant Staphylococcus aureus disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Recognition and management of infections caused by vancomycin-intermediate Staphylococcus aureus (VISA) and heterogenous VISA (hVISA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Vancomycin-resistant staphylococci and enterococci: epidemiology and control

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Novel mechanism of antibiotic resistance originating in vancomycin-intermediate Staphylococcus aureus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Comparison of Tn1546-like elements in vancomycin-resistant Staphylococcus aureus isolates from Michigan and Pennsylvania

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Vancomycin-resistant Staphylococcus aureus isolate from a patient in Pennsylvania

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Phase II, randomized, double-blind, multicenter study comparing the safety and pharmacokinetics of tefibazumab to placebo for treatment of Staphylococcus aureus bacteremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Antibacterial agents based on the cyclic D,L-alpha-peptide architecture

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Therapeutic effect of modified oligopeptides from the beetle Allomyrina dichotoma on methicillin-resistant Staphylococcus aureus (MRSA) infection in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

The cathelicidins--structure, function and evolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Roles of antimicrobial peptides such as defensins in innate and adaptive immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Host defence peptides from invertebrates--emerging antimicrobial strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Staphylococcus aureus infective endocarditis: diagnosis and management guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

In vitro activity of vancomycin, quinupristin/dalfopristin, and linezolid against intact and disrupted biofilms of staphylococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Linezolid for the treatment of patients with endocarditis: a systematic review of the published evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Treatment of methicillin-resistant staphylococcus aureus infections with quinupristin-dalfopristin in patients intolerant of or failing prior therapy. For the Synercid Emergency-Use Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Good clinical outcomes but high rates of adverse reactions during linezolid therapy for serious infections: a proposed protocol for monitoring therapy in complex patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Methicillin-resistant, quinupristin-dalfopristin-resistant Staphylococcus aureus with reduced sensitivity to glycopeptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin-aztreonam

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Diminished susceptibility to daptomycin accompanied by clinical failure in a patient with methicillin-resistant Staphylococcus aureus bacteremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Importance of beta-lactamase inactivation in treatment of experimental endocarditis caused by Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

A prospective multicenter study of Staphylococcus aureus bacteremia: incidence of endocarditis, risk factors for mortality, and clinical impact of methicillin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Failure of treatment with teicoplanin at 6 milligrams/kilogram/day in patients with Staphylococcus aureus intravascular infection. The Infectious Diseases Consortium of Oregon

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Endocarditis caused by methicillin-resistant Staphylococcus aureus: treatment failure with linezolid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Biofilms and antibiotic therapy: is there a role for combating bacterial resistance by the use of novel drug delivery systems?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Prosthetic-joint infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Staphylococcus aureus bacteremia in patients with permanent pacemakers or implantable cardioverter-defibrillators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Prolonged suppressive antibiotic therapy for infected orthopedic prostheses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Dalbavancin compared with vancomycin for prevention of Staphylococcus aureus colonization of devices in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Effect of delayed infection control measures on a hospital outbreak of methicillin-resistant Staphylococcus aureus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Hand hygiene: improved standards and practice for hospital care

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Mupirocin-resistant, methicillin-resistant Staphylococcus aureus: does mupirocin remain effective?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

A randomized, controlled trial of tea tree topical preparations versus a standard topical regimen for the clearance of MRSA colonization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Oxazolidinone antibiotics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Daptomycin: the first approved lipopeptide antimicrobial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

In vitro activities of tigecycline against erythromycin-resistant Streptococcus pyogenes and Streptococcus agalactiae: mechanisms of macrolide and tetracycline resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Management and outcome of children with skin and soft tissue abscesses caused by community-acquired methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Clindamycin treatment of methicillin-resistant Staphylococcus aureus infections in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Trimethoprim-sulfamethoxazole plus topical antibiotics as therapy for acute otitis media with otorrhea caused by community-acquired methicillin-resistant Staphylococcus aureus in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Antibiotics currently used in the treatment of infections caused by Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Once-daily intravenous cefazolin plus oral probenecid is equivalent to once-daily intravenous ceftriaxone plus oral placebo for the treatment of moderate-to-severe cellulitis in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Methicillin-ResistantS. aureusInfections among Patients in the Emergency Department

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Development of resistance to ciprofloxacin, rifampin, and mupirocin in methicillin-susceptible and -resistant Staphylococcus aureus isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Emergence and spread of rifampicin-resistant, methicillin-resistant Staphylococcus aureus during vancomycin-rifampicin combination therapy in an intensive care unit

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Dumb and dumber--the potential waste of a useful antistaphylococcal agent: emerging fusidic acid resistance in Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Fusidic acid resistance in community isolates of methicillin susceptible Staphylococcus aureus and the use of topical fusidic acid: a retrospective case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Are the new quinolones appropriate treatment for community-acquired methicillin-resistant Staphylococcus aureus?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Fluoroquinolones and the risk for methicillin-resistant Staphylococcus aureus in hospitalized patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Trimethoprim-sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Reduction in incidence of nosocomial methicillin-resistant Staphylococcus aureus (MRSA) infection in an intensive care unit: role of treatment with mupirocin ointment and chlorhexidine baths for nasal carriers of MRSA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Long-term efficacy of mupirocin in the prevention of infections with meticillin-resistant Staphylococcus aureus in a gastroenterology unit

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

High-level mupirocin resistance within methicillin-resistant Staphylococcus aureus pandemic lineages

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Staphylococcus aureus with Heterogeneous Resistance to Vancomycin: Epidemiology, Clinical Significance, and Critical Assessment of Diagnostic Methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Isolates with low-level vancomycin resistance associated with persistent methicillin-resistant Staphylococcus aureus bacteremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Dalbavancin activity against selected populations of antimicrobial-resistant Gram-positive pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

New antibiotics for the treatment of severe staphylococcal infection in the critically ill patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Linezolid and serotonergic drug interactions: a retrospective survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin. Synercid Skin and Skin Structure Infect

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Treatment of gram-positive nosocomial pneumonia. Prospective randomized comparison of quinupristin/dalfopristin versus vancomycin. Nosocomial Pneumonia Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Activity of daptomycin against multi-resistant Gram-positive bacteria including enterococci and Staphylococcus aureus resistant to linezolid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

In vitro synergy of daptomycin plus rifampin against Enterococcus faecium resistant to both linezolid and vancomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Daptomycin for the treatment of gram-positive bacteremia and infective endocarditis: a retrospective case series of 31 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Uncertain efficacy of daptomycin for prosthetic joint infections: a prospective case series.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Severe myopathy and possible hepatotoxicity related to daptomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Staphylococcus aureus: the search for novel targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Novel antibacterial agents for the treatment of serious Gram-positive infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

The crisis of resistance: identifying drug exposures to suppress amplification of resistant mutant subpopulations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Immune evasion by staphylococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Release of antimicrobial peptide Dhvar-5 from polymethylmethacrylate beads.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Antimicrobial peptides of multicellular organisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Bacteriophage therapy: a revitalized therapy against bacterial infectious diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Experimental bacteriophage protection against Staphylococcus aureus abscesses in a rabbit model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Experimental protection of mice against lethal Staphylococcus aureus infection by novel bacteriophage phi MR11.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Potential of the polyvalent anti-Staphylococcus bacteriophage K for control of antibiotic-resistant staphylococci from hospitals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Targeting antibacterial agents by using drug-carrying filamentous bacteriophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Lysostaphin Disrupts Staphylococcus aureus and Staphylococcus epidermidis Biofilms on Artificial Surfaces

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Biofilms: survival mechanisms of clinically relevant microorganisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Quorum sensing in Staphylococcus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Prevention of Staphylococcus aureus biofilm on dialysis catheters and adherence to human cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Staphylococcal vaccines and immunotherapy: to dream the impossible dream?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Toxins of Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Relationships between Staphylococcus aureus genetic background, virulence factors, agr groups (alleles), and human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Superantigen antagonist peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Staphylococcus aureus RNAIII and the endoribonuclease III coordinately regulate spa gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Autoinducer of virulence as a target for vaccine and therapy against Staphylococcus aureus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Origin, structure, and activity in vitro and in vivo of dalbavancin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Antistaphylococcal activity of DX-619, a new des-F(6)-quinolone, compared to those of other agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Purification, sequence and antibacterial activity of two novel sapecin homologues from Sarcophaga embryonic cells: similarity of sapecin B to charybdotoxin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Why is big Pharma getting out of antibacterial drug discovery?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Development of daptomycin for gram-positive infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Diagnosis and management of Staphylococcus aureus bacteraemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Diagnosis and management of catheter-related bloodstream infections due to Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Management of bone and joint infections due to Staphylococcus aureus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Diagnosis and management of Staphylococcus aureus infections of the skin and soft tissue.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Detection of gyrA gene mutations associated with ciprofloxacin resistance in methicillin-resistant Staphylococcus aureus: analysis by polymerase chain reaction and automated direct DNA sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Clonal dissemination and mupA gene polymorphism of mupirocin-resistant Staphylococcus aureus isolates from long-term-care facilities in South Korea

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

Treating foot infections in diabetic patients: a randomized, multicenter, open-label trial of linezolid versus ampicillin-sulbactam/amoxicillin-clavulanate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

The clinical efficacy of continuous-infusion flucloxacillin in serious staphylococcal sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.1

21 January 2018

Identifiers

DOI

10.1517/14728214.12.1.1

1 reference

16 August 2017

1 reference

PubMed ID

17355211